Comparison of Inflammatory Response After Implantation of Sirolimus- and Paclitaxel-Eluting Stents in Porcine Coronary Arteries

被引:177
作者
Wilson, Gregory J. [1 ]
Nakazawa, Gaku [2 ]
Schwartz, Robert S. [3 ]
Huibregtse, Barbara [4 ]
Poff, Bradley [4 ]
Herbst, Thomas J. [4 ]
Baim, Donald S. [4 ]
Virmani, Renu [2 ]
机构
[1] Univ Toronto, Hosp Sick Children, Dept Lab Med & Pathobiol, Res Inst, Toronto, ON M5G 1X8, Canada
[2] Int Registry Pathol, CVPath, Gaithersburg, MD USA
[3] Minneapolis Heart Inst Fdn, Minnesota Cardiovasc Res Inst, Minneapolis, MN USA
[4] Boston Sci Corp, Div Clin Sci, Natick, MA USA
关键词
angioplasty; coronary disease; inflammation; pathology; stents; THROMBOSIS; MODEL;
D O I
10.1161/CIRCULATIONAHA.107.730010
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background-Although both sirolimus (CYPHER) and paclitaxel (TAXUS) drug-eluting stents have demonstrated efficacy and safety in clinical trials, human autopsy data have raised concerns about long-term healing and the potential for local inflammatory reactions. Methods and Results-Overlapping stents (CYPHER drug-eluting stents, Bx SONIC bare metal stents, TAXUS drug-eluting stents, and Liberte bare metal stents) were implanted in noninjured coronary arteries of 58 domestic swine. Histopathological evaluation of proximal, overlapped, and distal stented segments was determined with emphasis on inflammation at 30, 90, and 180 days. Circumferential granulomatous inflammation in all stented segments was defined as inflammation consisting of macrophages, multinucleated giant cells, lymphocytes, and granulocytes, including many eosinophils, adjacent to almost all struts. Circumferential granulomatous inflammation was more prevalent in CYPHER (9 of 23, 39%) compared with TAXUS (1 of 21, 5%; P=0.01) and control bare metal stents (0 of 44) in the combined 90- and 180-day cohorts. Only CYPHER specimens showed marked adventitial inflammation (P=0.0025) and fibrosis (P=0.0055) accompanied by extensive remodeling. Fibrin deposition within neointima and medial smooth muscle cell death were greater (both P<0.001) in TAXUS than CYPHER at 30 days, with more fibrin in TAXUS than CYPHER through 90 days (P<0.05). Conclusions-Although these data cannot be directly extrapolated to humans, the high prevalence in this porcine model of diffuse granulomatous inflammation seen with CYPHER stents, persisting at 180 days and associated with extensive remodeling of the artery, and persistent para-strut fibrin deposition with TAXUS stents emphasize the need for further investigation of biocompatibility with these and other novel combination drug/polymer drug-eluting stents. (Circulation. 2009; 120: 141-149.)
引用
收藏
页码:141 / U75
页数:11
相关论文
共 12 条
[1]   Long-term effects of polymer-based, slow-release, sirolimus-eluting stents in a porcine coronary model [J].
Carter, AJ ;
Aggarwal, M ;
Kopia, GA ;
Tio, F ;
Tsao, PS ;
Kolata, R ;
Yeung, AC ;
Llanos, G ;
Dooley, L ;
Falotico, R .
CARDIOVASCULAR RESEARCH, 2004, 63 (04) :617-624
[2]   Incomplete stent apposition and very late stent thrombosis after drug-eluting stent implantation [J].
Cook, Stephane ;
Wenaweser, Peter ;
Togni, Mario ;
Billinger, Michael ;
Morger, Cyrill ;
Seiler, Christian ;
Vogel, Rolf ;
Hess, Otto ;
Meier, Bernhard ;
Windecker, Stephan .
CIRCULATION, 2007, 115 (18) :2426-2434
[3]   Stent thrombosis redux - The FDA perspective [J].
Farb, Andrew ;
Boam, Ashley B. .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (10) :984-987
[4]   Vascular responses to drug eluting stents - Importance of delayed healing [J].
Finn, Aloke V. ;
Nakazawa, Gaku ;
Joner, Michael ;
Kolodgie, Frank D. ;
Mont, Erik K. ;
Gold, Herman K. ;
Virmani, Renu .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2007, 27 (07) :1500-1510
[5]   Pathological correlates of late drug-eluting stent thrombosis - Strut coverage as a marker of endothelialization [J].
Finn, Aloke V. ;
Joner, Michael ;
Nakazawa, Gaku ;
Kolodgie, Frank ;
Newell, John ;
John, Mike C. ;
Gold, Herman K. ;
Virmani, Renu .
CIRCULATION, 2007, 115 (18) :2435-2441
[6]   Differential response of delayed healing and persistent inflammation at sites of overlapping sirolimus- or paclitaxel-eluting stents [J].
Finn, AV ;
Kolodgie, FD ;
Harnek, J ;
Guerrero, LJ ;
Acampado, E ;
Tefera, K ;
Skorija, K ;
Weber, DK ;
Gold, HK ;
Virmani, R .
CIRCULATION, 2005, 112 (02) :270-278
[7]   Pathology of drug-eluting stents in humans - Delayed healing and late thrombotic risk [J].
Joner, Michael ;
Finn, Aloke V. ;
Farb, Andrew ;
Mont, Erik K. ;
Kolodgie, Frank D. ;
Ladich, Elena ;
Kutys, Robert ;
Skorija, Kristi ;
Gold, Herman K. ;
Virmani, Renu .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2006, 48 (01) :193-202
[8]  
SCHWARTZ RS, 1992, J AM COLL CARDIOL, V19, P275
[9]   Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents [J].
Stone, Gregg W. ;
Moses, Jeffrey W. ;
Ellis, Stephen G. ;
Schofer, Joachim ;
Dawkins, Keith D. ;
Morice, Marie-Claude ;
Colombo, Antonio ;
Schampaert, Erick ;
Grube, Eberhard ;
Kirtane, Ajay J. ;
Cutlip, Donald E. ;
Fahy, Martin ;
Pocock, Stuart J. ;
Mehran, Roxana ;
Leon, Martin B. .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (10) :998-1008
[10]   Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model [J].
Suzuki, T ;
Kopia, G ;
Hayashi, S ;
Bailey, LR ;
Llanos, G ;
Wilensky, R ;
Klugherz, BD ;
Papandreou, G ;
Narayan, P ;
Leon, MB ;
Yeung, AC ;
Tio, F ;
Tsao, PS ;
Falotico, R ;
Carter, AJ .
CIRCULATION, 2001, 104 (10) :1188-1193